12(S)-HETE mediates diabetes-induced endothelial dysfunction by activating intracellular endothelial cell TRPV1

Mandy Otto, …, Eric R. Gross, Nana-Maria Wagner


Find the latest version:
https://jci.me/136621/pdf
Patients with diabetes develop endothelial dysfunction shortly after diabetes onset that progresses to vascular disease underlying the majority of diabetes-associated comorbidities. Increased lipid peroxidation, mitochondrial calcium overload, and mitochondrial dysfunction are characteristics of dysfunctional endothelial cells in diabetic patients. We here identified that targeting the lipid peroxidation product 12(S)-hydroxyeicosatetraenoic acid–induced [12(S)-HETE–induced] activation of the intracellularly located cation channel transient receptor potential vanilloid 1 (TRPV1) in endothelial cells is a means to causally control early-stage vascular disease in type 1 diabetic mice. Mice with an inducible, endothelium-specific 12/15-lipoxygenase (12/15Lox) knockout were protected similarly to TRPV1-knockout mice from type 1 diabetes–induced endothelial dysfunction and impaired vascular regeneration following arterial injury. Both 12(S)-HETE in concentrations found in diabetic patients and TRPV1 agonists triggered mitochondrial calcium influx and mitochondrial dysfunction in endothelial cells, and 12(S)-HETE effects were absent in endothelial cells from TRPV1-knockout mice. As a therapeutic consequence, we found that a peptide targeting 12(S)-HETE–induced TRPV1 interaction at the TRPV1 TRP box ameliorated diabetes-induced endothelial dysfunction and augmented vascular regeneration in diabetic mice. Our findings suggest that pharmacological targeting of increased endothelial lipid peroxidation can attenuate diabetes-induced comorbidities related to vascular disease.

**Conflict of interest:** ERC holds a patent on “Peptide modulators of specific calcineurin protein–protein interactions” (US Application Serial No. 16/082,313) that includes the V1-cal peptide.

**Copyright:** © 2020, American Society for Clinical Investigation.

**Submitted:** January 21, 2020; **Accepted:** June 17, 2020; **Published:** August 17, 2020.

**Reference information:** J Clin Invest. 2020;130(9):4999–5010. https://doi.org/10.1172/JCI136621.

---

**Introduction**

Millions of people worldwide suffer from diabetes, and the numbers are increasing. Among children, the incidence of type 1 diabetes mellitus currently doubles every 20 years (1). Diabetes leads to multiple comorbidities, such as heart disease, kidney dysfunction, loss of vision, and impaired wound healing, that reduce quality of life and life expectancy of diabetic patients (2). These comorbidities are almost exclusively attributable to vascular disease that is initiated by diabetes-induced loss of endothelial integrity. In children who — apart from hyperglycemia — do not exhibit any additional cardiovascular risk factors, the endothelium loses its ability to regulate vasotonus already a few years after disease onset (3). Endothelial dysfunction correlates to vascular disease progression and severity that are relevant to the outcome of patients with diabetes (4). Despite guideline-based medical therapy, diabetic patients develop comorbidities secondary to vascular disease with an unacceptably high incidence. Moreover, the mechanisms of diabetes-induced vascular pathology are incompletely understood, and therapeutic options specifically targeting vascular disease initiation in diabetes are lacking.

In patients with diabetes, endothelial cells exhibit damaged mitochondria, mitochondrial dysfunction, and a decreased oxidative capacity (5). Increasing evidence identifies that mitochondrial dysfunction is linked to mitochondrial calcium overload that contributes to loss of mitochondrial membrane potential, impaired mitochondrial respiration, and excessive generation of mitochondrial reactive oxygen species (6). The defects in mitochondrial calcium handling further correlate with a reduced endothelial bioavailability of nitric oxide that results in defective endothelium-dependent vasodilation, one of the central characteristics of diabetes-induced endothelial dysfunction (7, 8). However, the mediators of diabetes-induced disturbances of mitochondrial calcium homeostasis have not been fully elucidated so far, and there is currently no option to causally control early-stage vascular disease in diabetes.

Hyperglycemia induces increased arachidonic acid breakdown by 12-lipoxygenases (12LOXs) in endothelial cells that results in increased production of endothelial 12(S)-hydroperoxy-5Z,8Z,10E,14Z-eicosatetraenoic acid [12(S)-HpETE] and its stable metabolite 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE] (9). 12(S)-HETE plasma concentrations are particularly elevated in children with newly diagnosed type 1 diabetes (10) and adult diabetic patients with vascular complications such as coronary artery disease and early renal disease (11, 12). However, it is unclear to...
what extent and how 12(S)-HETE contributes to vascular pathology in diabetes. 12(S)-HETE is a potent activator of transient receptor potential vanilloid 1 (TRPV1) (13). TRPV1 is a nonselective cation channel primarily gating calcium that is activated by physical and chemical stimuli, such as heat, acidic conditions, and capsaicin, the pungent compound of the red chili pepper (14). In addition to its expression in sensory neurons, where it transmits the sensation of pain in response to noxious stimuli, TRPV1 is expressed in vascular cells, including endothelial cells (15). While TRPV1 has been intensively characterized at the cell surface, recent studies suggest intracellular localizations of TRPV1 and that TRPV1 plays a fundamental role in cellular calcium homeostasis (16). TRPV1 is implicated in the constitutive regulation of mitochondrial calcium influx (17), and mitochondrial calcium changes induced by TRPV1 activation result in mitochondrial dysfunction and can trigger calcium-dependent cellular dysfunction (18).

We here aimed to identify a previously unrecognized mechanism of 12(S)-HETE–induced TRPV1 activation that crucially mediates early-stage vascular disease initiation in a mouse model of type 1 diabetes. By generating endothelium-specific 12/15-lipoxygenase–knockout (12/15LO-knockout) mice and using TRPV1-knockout mice, we showed that both 12(S)-HETE and TRPV1 are required for the development of endothelial dysfunction in diabetic mice. In vitro we verified that, by activating intracellular TRPV1 in endothelial cells, 12(S)-HETE induces mitochondrial calcium changes that result in mitochondrial dysfunction. As a therapeutic implication of this mechanism, we show that a peptide constituting an amino acid sequence of the highly conserved TRP box at the C-terminal end of TRPV1 identified as a potential 12(S)-HETE/TRPV1 interaction site can serve as a decoy and ameliorate TRPV1 activation in the presence of 12(S)-HETE, thus protecting mice from diabetes-induced endothelial dysfunction.

Results

12(S)-HETE is a mediator of diabetes-induced endothelial dysfunction and mitochondrial dysfunction in endothelial cells. To assess a role of endothelium-derived 12(S)-HETE in diabetes-induced endothelial dysfunction, we generated mice with an endothelium-specific, tamoxifen-inducible knockout of the 12(S)-HETE–generating enzyme 12/15-lipoxygenase (12/15LO in mice) by breeding homozygous 12/15Lo<sup>fl/fl</sup> mice exhibiting loxP sites flanking exons 2–5 of the 12/15Lo gene (19) to homozygosity with mice expressing Cre recombinase under the tamoxifen-inducible endothelium-specific vascular endothelial cadherin (VE-cadherin; Cdh5) promoter (ref. 20 and Figure 1A). Type 1 diabetes was induced in adult mice by a single streptozotocin injection, and similarly increased blood glucose levels were verified in WT, tamoxifen-treated Cre-negative, and Cre-positive mice 4 days and 4 weeks after injection (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI136621DS1). While Cre-negative diabetic mice showed an increase in plasma 12(S)-HETE levels under diabetic conditions that was comparable to the increase seen in diabetic WT mice (361.3 ± 49.1 and 499.8 ± 137.3 ng/mL vs. 92.5 ± 15.5 and 155.2 ± 67.3 ng/mL in nondiabetic respective controls), Cre-positive diabetic mice exhibited no increase in plasma levels in the presence of type 1 diabetes (215.5 ± 51.4 vs. 177 ± 33.4 ng/mL in nondiabetic Cre-positive control mice) (Supplemental Figure 2). Four weeks after streptozotocin injection, impaired endothelium-dependent vasodilation was exhibited in diabetic, tamoxifen-treated Cre-negative control mice (P < 0.001 vs. nondiabetic tamoxifen-treated Cre-negative mice) that was partly restored in endothelium-specific 12/15Lo-knockout mice (P < 0.001 vs. diabetic Cre-negative animals; Figure 1, B and C). In a second model, we compared the diabetic vascular response to injury by morphometrically assessing neointimal hyperplasia 3 weeks after ferric chloride–induced carotid artery injury. While diabetic Cre-negative mice showed increased neointima area and luminal stenosis compared with nondiabetic control mice (P < 0.001 and P < 0.05, respectively), Cre-positive diabetic mice exhibited similarly reduced neointima area and luminal stenosis compared with nondiabetic mice (Supplemental Figure 3). We next assessed whether exogenous administration of 12(S)-HpETE, the primary 12LOX metabolite and precursor of 12(S)-HETE, to human endothelial cells in vitro can affect mitochondrial integrity and endothelial cell function under normal-glucose conditions. Exposure of endothelial cells to 12(S)-HpETE in concentrations reported in patients with diabetes induced mitochondrial calcium influx and reduced mitochondrial membrane potential. Similar concentrations of 12(S)-HpETE impaired mitochondrial respiration (Figure 1, D–F) and reduced the ability of endothelial cells to form capillary-like networks on extracellular matrix (Supplemental Figure 4). To test whether increased 12(S)-HpETE levels contribute to impaired mitochondrial function induced by high levels of glucose, effects of 12LOX inhibitors were evaluated. Culture of endothelial cells under high-glucose conditions (30 mM) showed impaired mitochondrial function that was restored by exposure to the 12LOX inhibitors baicalein and phenidone (Figure 1, G and H).

Expression and function of TRPV1 in human endothelial cells. 12(S)-HpETE is a potent agonist of TRPV1, inducing calcium flux (13). Exposure of patched endothelial cells to 10 μM capsaicin resulted in robust currents that were antagonized with 10 μM of the specific TRPV1 antagonist 4-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylylethyl)phenyl]-1-piperazine-carboxamide (BCTC) (Figure 2A). Western blot using TRPV1-specific antibodies (21) revealed the expression of an approximately 95-kDa–molecular weight protein. At the cell surface, TRPV1 is found glycosylated, resulting in a molecular weight of about 110 kDa (22), the protein size detected in murine dorsal root ganglion cells particularly enriched in TRPV1. In accordance with previous observations in other cell types such as cardiomyocytes (23), the existence of the 95 kDa protein size suggests that TRPV1 is located not only at the plasma membrane on endothelial cells but also intracellularly. Immunohistochemical analysis revealed that TRPV1 colocalizes with endothelial cell mitochondria (Figure 2C), and cell fractionation showed TRPV1 particularly enriched in organelle fractions containing mitochondria (Figure 2B). Further functional analysis of TRPV1 using capsaicin as agonist revealed an increase in cytosolic calcium in endothelial cells upon exposure that persisted when calcium was removed from extracellular medium (Figure 2D). Similar increases in calcium levels were observed in endothelial cell mitochondria, but these effects were absent after depletion of intracellular calcium stores (Figure 2E), suggesting that TRPV1 mobilizes and gates calcium from intracellular stores into the cytosol and — primarily or secondarily — to the mitochondria. Increase
Figure 1. 12(S)-HETE mediates diabetes-induced endothelial and mitochondrial dysfunction. (A) Mice used to generate endothelium-specific 12/15Lo knockout mice. (B) Carbamoylcholine (Cch) induced vasorelaxation in murine mesenteric resistance arteries preconstricted with 10^{-5} M phenylephrine (Phe) in 12/15Lo^{+/+} mice positive (Cre^{-/-}) or negative (Cre^{-/-}) for the Cre transgene. Type 1 diabetes was induced by injection of streptozotocin (STZ), dissolved in sodium citrate (NaCi) serving as vehicle control in nondiabetic mice. ***P < 0.001 vs. as indicated, 2-way ANOVA/Bonferroni. n = 5 mice per group. M/L, moles per liter. (C) Representative pictures of Cch-induced vasorelaxation at 10^{-5} M. (D) Mitochondrial calcium influx over time detected as fluorescence intensity changes by flow cytometry in rhodamine-2–loaded (Rhod-2–loaded) human endothelial cells stimulated with 12(S)-HpETE, with time of addition indicated by arrows. Upper panel shows a representative flow cytometry dot plot, lower panel the quantitative summary of n = 6 independent experiments. Ethanol (EtOH) served as vehicle control. *P < 0.05 vs. mean baseline, 2-way ANOVA/Bonferroni. (E) Mitochondrial respiration (oxygen consumption rate, OCR) measured by a Seahorse extracellular flux analyzer. *P < 0.05, ***P < 0.001 vs. EtOH, 1-way ANOVA/Bonferroni, n = 5–7 experiments per group. (F) Decline of mitochondrial membrane potential detected by flow cytometry as loss of red fluorescence. Two micromolar CCCP was used as positive control. *P < 0.05, **P < 0.01, ***P < 0.001 vs. EtOH, 1-way ANOVA/Bonferroni, n = 5–7 independent experiments. (G) Extracellular flux analysis of high-glucose-exposed human endothelial cells. Inhibition of 12LOX by baicalein or phenidone improves mitochondrial OCR. Maximum mitochondrial respiration was assessed after addition of oligomycin (Oligo) and FCCP indicated by arrows. **P < 0.01 baicalein, **P < 0.01 phenidone vs. d-glucose only, 2-way ANOVA/Bonferroni. Pooled data from n = 5–8 independent experiments with each variant each analyzed in triplicate. (H) Summary of basal respiration data. **P < 0.01 vs. l-glucose, ***P < 0.01 vs. d-glucose, 1-way ANOVA/Bonferroni, n = 8 independent experiments. All graphs show mean ± SEM.
in mitochondrial calcium was further associated with loss of mitochondrial membrane potential and impaired mitochondrial respiration (Figure 2, F and G) that were further accompanied by impaired endothelial cell function (Supplemental Figure 5).

**TRPV1 expression and function under high-glucose conditions and effects of TRPV1 deficiency in diabetic mice.** To evaluate whether TRPV1 expression and function are affected by high-glucose conditions, patch clamp analysis of capsaicin-evoked responses was repeated in endothelial cells subjected to high-glucose conditions for 72 hours. In high-glucose-treated endothelial cells 10 μM capsaicin revealed induction of currents comparable to that observed previously (Figure 3A vs. Figure 2A). Western blot experiments showed that TRPV1 expression remained unchanged under high-glucose conditions in endothelial cells in vitro within 24 hours and up to 5 consecutive days (exemplarily shown in Figure 3B after 48 hours). To test whether TRPV1 deficiency is of relevance to diabetes-induced endothelial dysfunction, type 1 diabetes mellitus was induced in Trpv1-knockout and WT mice. Trpv1 knockout equally responded to streptozotocin injection with developing high glucose levels (Supplemental Figure 1), and mean 12(S)-HETE plasma levels increased more than 3-fold in diabetic compared with nondiabetic plasma levels (169.6 ± 41.6 vs. 47.5 ± 6.2 ng/mL, P < 0.01; Supplemental Figure 2). In contrast to diabetic WT mice, diabetic Trpv1-knockout mice exhibited preserved endothelium-dependent vasorelaxation (P < 0.001; Figure 3C) and showed no impairment of regenerative responses after arterial injury (Supplemental Figure 6). In vitro, TRPV1 activation with capsaicin induced comparable decline in mitochondrial function in human endothelial cells cultured under high-glucose conditions versus under normal-glucose conditions (Figure 3D). Antagonizing TRPV1 with the specific antagonist BCTC in endothelial cells subjected to high-d-glucose augmented mitochondrial respiration, and endothelial cells isolated from Trpv1-knockout mice were protected against high-glucose-induced mitochondrial dysfunction (Figure 3, E and F), suggesting that TRPV1 inhibition or absence exerts beneficial effects for the preservation of mitochondrial and endothelial cell function under high-glucose conditions.

**Importance of TRPV1 for mediating 12(S)-HETE effects.** After verifying that both 12(S)-HETE and functional TRPV1 play a role in diabetes-induced endothelial dysfunction, we aimed to test the importance of TRPV1 for mediating 12(S)-HpETE effects. We first performed patch clamp experiments revealing that 12(S)-HpETE induced currents in endothelial cells comparable to those induced by the TRPV1 agonist capsaicin and that these currents could similarly be antagonized by the TRPV1 antagonist BCTC (Figure 4A). Next, we analyzed 12(S)-HpETE-evoked mitochondrial calcium influx in murine pulmonary endothelial cells isolated from WT and Trpv1-knockout mice. While 12(S)-HpETE induced mitochondrial calcium influx in endothelial cells from WT mice, these effects were absent in endothelial cells isolated from Trpv1-knockout mice (Figure 4B). Similar results were obtained regarding the effects of 12(S)-HETE on mitochondrial function, with 12(S)-HpETE effects absent in murine endothelial cells isolated from Trpv1-knockout in contrast to endothelial cells from WT mice (Figure 4C). Findings of impaired mitochondrial function further translated to endothelial function assessed in vitro as endothelial capillary-like tube formation on extracellular matrix equivalents. Here, 12(S)-HpETE impaired tube formation in endothelial cells isolated from WT but not Trpv1-knockout mice. 12(S)-HpETE effects in endothelial cells from WT mice were diminished in the presence of the TRPV1 antagonist BCTC (Figure 4, D and E), providing evidence that functional TRPV1 is required for 12(S)-HpETE to induce mitochondrial and endothelial cell dysfunction. In addition to 12(S)-HpETE, the human 12LOX and murine 12/15LO enzyme also generates 15(S)-HpETE, and 15(S)-HpETE also activates TRPV1, although with reduced potency compared with 12(S)-HpETE (13). To assess a possible role of 15(S)-HpETE in contributing to the observed effects in type 1 diabetes, 15(S)-HpETE plasma concentrations were determined in diabetic and nondiabetic mice. 15(S)-HpETE levels were 10-fold lower in nondiabetic mice compared with 12(S)-HpETE concentrations (20.8 ± 1.3 vs. 239.7 ± 60.48 ng/mL) and were not elevated under diabetic conditions (80.2 ± 13.9 ng/mL in diabetic mice, P = NS vs. nondiabetic mice; Supplemental Figure 7A). In line with the previously reported potency of 15(S)-HpETE to activate TRPV1, exogenously administered 15(S)-HpETE also triggered mitochondrial calcium influx, although less potently compared with 12(S)-HpETE in human endothelial cells. In contrast to 12(S)-HpETE, 15(S)-HpETE did not induce mitochondrial dysfunction in endothelial cells in vitro (Supplemental Figure 7B–D).

**Targeting the TRPV1 TRP box ameliorates diabetes-induced vascular pathology.** Based on the findings reported above, we hypothesized that abrogation of 12(S)-HpETE-mediated TRPV1 activation can reduce high-glucose-induced mitochondrial dysfunction in endothelial cells and protect against vascular pathology in diabetes. To block 12(S)-HpETE-induced TRPV1 activation, we used a peptide constituting parts of the conserved TRP box of TRPV1 coupled to a transactivator of transcription (TAT) linker previously used to inhibit TRPV1 activation (V1-cal; Figure 5A and ref. 23). Patch clamp analysis confirmed that 12(S)-HpETE was unable to evoke currents in V1-cal-loaded human endothelial cells in contrast to the 12(S)-HpETE response detected in cells loaded with TAT linker protein (Figure 5B). Preincubation with V1-cal abolished 12(S)-HpETE-induced mitochondrial calcium influx in contrast to 12(S)-HpETE effects in endothelial cells preincubated with the TAT linker protein or a scrambled version of V1-cal (V1-scr) coupled to TAT used as controls (Figure 5C). V1-cal but not TAT or V1-scr reduced 12(S)-HpETE-induced decrease of mitochondrial respiration (Figure 5D) and abolished the effects of 12(S)-HpETE that impaired endothelial cell capillary-like tube formation (Supplemental Figure 8). Notably, neither V1-cal, the TAT linker protein, nor V1-scr altered 12LOX expression in human endothelial cells in vitro (Supplemental Figure 9). In vivo, injection of V1-cal, TAT, or V1-scr for 4 consecutive days 4 weeks after streptozotocin injection revealed that V1-cal but not TAT or V1-scr was able to improve endothelial dysfunction in diabetic mice (Figure 5E). Continuous delivery of V1-cal via subcutaneously implanted osmotic minipumps for 3 weeks after arterial injury in diabetic mice improved vascular regeneration compared with histomorphometrically assessed quantitative measures of nondiabetic control mice (Supplemental Figure 10). In V1-cal–treated diabetic mice, 12(S)-HETE concentrations were undetectable in murine plasma, possibly owing to formation of complexes of 12(S)-HpETE with V1-cal.
The Journal of Clinical Investigation

RESEARCH ARTICLE

5003
jci.org   Volume 130   Number 9   September 2020

from diabetic patients. We identify the cation channel TRPV1 at a previously unrecognized intracellular localization in endothelial cells where it transmits 12(S)-HpETE effects at the mitochondria. By targeting 12(S)-HpETE interaction with TRPV1 at the TRPV1 C-terminal TRP box, we uncovered a potential pharmacological strategy that could allow causal control of diabetes-induced vascular disease initiation and progression.

Discussion

Type 1 and type 2 diabetes mellitus inevitably lead to vascular disease that almost exclusively determines the multiple comorbidities related to diabetes. Despite the implementation of traditional strategies to lower cardiovascular risk, diabetic patients have a 7 to 10 times higher risk of suffering from adverse cardiovascular events (24), demanding a more specific understanding of vascular disease pathology in diabetes. We here identify that elevated plasma concentrations of 12(S)-HETE directly link the hyperglycemic condition to vascular disease initiation in diabetes. We show that 12(S)-HpETE induces mitochondrial calcium increase and mitochondrial dysfunction characteristic of endothelial cells.
dependent vasodilation can be assessed and quantified in diabetic patients and is an independent marker of cardiovascular risk and predictor of future adverse cardiovascular events (25). Endothelial dysfunction in diabetes is crucially connected to disturbance in intracellular calcium homeostasis and loss of mitochondrial integrity, but the mechanisms are incompletely understood (8, 26). In response to high glucose, endothelial cells upregulate 12LOX that metabolizes arachidonic acid to bioactive lipid mediators such as 12(S)-HpETE. Based on the observation that mice deficient in 12/15Lox, the mouse equivalent of human 12LOX, are resistant to chemical and high-fat diet-induced diabetes, 12LOX metabolites have been identified as mediators of oxidative stress in pancreatic β cell dysfunction during diabetes development. 12LOX inhibitors are currently discussed as pharmacological tools to limit diabetes initiation and possibly the complications related to disease progression (27). In the cardiovascular system, a correlation of 12LOX activity with reduced nitric oxide bioavailability and a proatherogenic phenotype has been well characterized in mouse models of 12/15Lox knockout and overexpression (reviewed in Gleissner et al., ref. 28).

To specify the role of 12LOX and its metabolites in the endothelium, we here generated mice with an inducible and endothelium-specific deletion of 12/15Lox. When diabetic, these mice showed no increase in 12(S)-HETE plasma concentration compared with their WT diabetic littermates. Since 12(S)-HpETE and its stable metabolite 12(S)-HETE can freely diffuse across cell membranes (29), our results suggest that endothelial cells are a major contributor to the increased 12(S)-HETE plasma concentrations in diabetic patients.

Although our findings thus mechanistically support the role for increased 12LOX metabolites in diabetic patients with renal and coronary vascular disease (11, 12), further studies are required to determine the exact source of increased 12(S)-HETE levels in diabetic mice in comparison with diabetic humans. Despite the presence of high glucose levels, diabetic mice with endothelial 12/15Lox knockout exhibited preserved endothelium-dependent vasodilation. In addition, they showed uncompromised vascular regenerative responses to arterial injury in contrast to their diabetic WT littermates, in which increased neointima formation was present 3 weeks after arterial injury. For arterial injury induction, we topicaly applied ferric chloride to the carotid artery that penetrates the vessel wall and causes endothelial denudation (30). After the initial thrombus formation and resolution, vascular repair is critically determined by re-endothelialization (31). Although we cannot extract specific cellular or molecular mechanistic insights into the underlying pathophysiology, these results can further support the notion that endothelial cell function in diabetic mice is sustained by 12/15Lox deletion. Already 30 years ago, hydroxyeicosatetraenoic acids were implicated in the mobilization of mitochondrial calcium, but a clinical implication of these findings remained unidentified (32). Here, we observed that 12(S)-HETE concentrations corresponding to those found in patients with diabetes (ranging from ~30 nM in ref. 11 to ~300 nM in ref. 10) increased mitochondrial calcium levels in human and murine endothelial cells, and these effects were associated with loss of mitochondrial membrane potential and mitochondrial dysfunction, the hallmarks of diabetes-induced endothelial dysfunction in diabetes.
dysfunction. Our results thus suggest that 12(S)-HETE is a direct mediator of endothelial dysfunction in diabetes and that increased 12(S)-HETE plasma levels could serve as a biomarker reflecting the degree of mitochondrial impairment, endothelial dysfunction, and thus vascular disease severity in patients with diabetes.

A known receptor of 12(S)-HETE is G protein–coupled receptor 31 (GPR31), and the 12(S)-HETE/GPR31 signaling axis is implicated in cancer metastasis and ischemia/reperfusion injury (33). While one study reported the presence of GPR31 in human endothelial cells at the mRNA level (34), we and others were unable to detect GPR31 in endothelial cells or the vasculature (35). In addition, 12(S)-HpETE effects on mitochondrial calcium influx and mitochondrial function were unaffected by the presence of pertussis toxin, suggesting that a G protein–coupled receptor is not involved in the effects of 12(S)-HpETE reported here (Supplemental Figure 11). In line with these results, the role of 12(S)-HETE in diabetes has been suggested to be mediated by other receptor molecules (33), which is further supported by reports that binding of 12(S)-HpETE to GPR31 is unable to evoke changes in intracellular calcium (36).

In addition to GPR31, 12(S)-HpETE is a known agonist of TRPV1 and activates TRPV1 with a $K_i$ of 350 nM (~117 ng/mL), a concentration found mostly in diabetic, not nondiabetic, rodents and humans. TRPV1 mediates increases in intracellular calcium levels in response to activation by capsaicin binding to intracellular localizations (14, 37). We here verified TRPV1 expression and function in endothelial cells by patch clamp analysis, Western blot, immunohistochemistry, and calcium flux analysis. Although TRPV1 is considered to primarily localize at the plasma membrane, immunohistochemistry of endothelial cells unraveled an intracellular localization of TRPV1 that was identical to the staining pattern of endothelial mitochondria. TRPV1 activation using capsaicin as agonist revealed that TRPV1 mobilizes calcium from intracellular calcium stores such as the endoplasmic reticulum (ER) that results in cytosolic calcium increase and — primarily or secondarily — in mitochondrial calcium uptake and increased mitochondrial calcium content. Intracellular localizations of TRPV1 have been identified previously, and a fundamental role of TRPV1 in regulating intracellular calcium has been proposed (16). In the regulation of

---

**Figure 4. 12(S)-HpETE effects on mitochondrial and endothelial function are mediated by TRPV1.** (A) Patch clamp experiments with human endothelial cells show that 700 nM 12(S)-HpETE induces currents comparable to those induced by 10 μM capsaicin and that these currents are antagonized by 10 μM of the TRPV1 antagonist BCTC. (B) Mitochondrial calcium increase induced by 1 μM 12(S)-HpETE added as indicated by the arrow and assessed as increase in fluorescence intensity of Rhod-2–loaded murine endothelial cells isolated from WT (dashed lines) versus Trpv1–/– mice. **P < 0.01 vs. baseline, 2-way ANOVA/Bonferroni, summary of n = 5 independent experiments. (C) Mitochondrial OCR is reduced by 100 nM 12(S)-HpETE in endothelial cells from WT but not Trpv1–/– mice. *P < 0.05, **P < 0.01 vs. EtOH or as indicated, 1-way ANOVA/Bonferroni, n = 5–10 independent experiments. (D and E) Effects of 12(S)-HpETE on endothelial capillary-like tube formation on Matrigel. Effects of 100 nM 12(S)-HpETE are absent in murine endothelial cells isolated from Trpv1–/– mice and endothelial cells isolated from WT mice in the presence of 10 μM of the TRPV1 antagonist BCTC. *P < 0.05, ***P < 0.001 vs. EtOH or as indicated, 1-way ANOVA/Bonferroni, n = 5–10 independent experiments. Scale bar: 500 μm. All data are presented as mean ± SEM.
Figure 5. Abrogation of the 12(S)-HpETE/TRPV1 interaction protects against diabetes-induced endothelial dysfunction. (A) Schematic of TRPV1 corresponding to amino acids 701–711 within the TRP box at the C-terminus of human TRPV1 linked to a TAT linker protein for intracellular entry. (B) Patch clamp experiments show that 700 nM 12(S)-HpETE evokes currents in endothelial cells loaded with 1 μM TAT linker, but not 1 μM V1-cal. Representative patch results from n = 10 independent experiments. (C) 12(S)-HpETE–induced mitochondrial calcium changes detected by flow cytometry [time point of addition of 12(S)-HpETE is indicated by the arrow] in human endothelial cells preincubated with either 1 μM V1-cal or 1 μM of a scrambled version of V1-cal (V1-scr) or TAT linker protein serving as controls. ***P < 0.001 vs. corresponding time point in V1-cal or EtOH, #P < 0.05, ##P < 0.01, ###P < 0.001 vs. TAT or V1-scr, 2-way ANOVA/Bonferroni, n = 5 independent experiments. (D) Assessment of mitochondrial function to evaluate effects of 1 μM V1-cal versus 1 μM TAT linker only (top 2 panels) or 1 μM V1-scr (bottom panel) on mitochondrial OCR induced by 1 μM 12(S)-HpETE. After 3 measurements, oligomycin was added before FCCP used to induce maximum respiration. *P < 0.05, **P < 0.01, 2-way ANOVA/Bonferroni. Variants were analyzed in triplicate on Seahorse miniplates, and n = 5 independent experiments were performed. All graphs show mean ± SEM. (E) Cch-induced vasorelaxation shows that repetitive intravenous application on 4 consecutive days of the V1-cal peptide (1 mg/kg/d), but not of the V1-scr peptide or the TAT linker protein only, to diabetic WT mice reduced endothelial dysfunction induced by diabetes (STZ). Sodium citrate (NaCl) was used as vehicle control. ***P < 0.001 vs. as indicated, 2-way ANOVA/Bonferroni. Means were generated for each individual animal by analysis of 2 arteries; n = 5 animals per group. Graph shows mean ± SEM.
nociception, crosstalk specifically between TRPV1 and the mitochondrial calcium shunting machinery was previously identified (38). In obesity-induced mitochondrial dysfunction, mitochondrial calcium increase is mediated by an increased formation of mitochondria-associated membranes (MAMs) and thus mitochondria/ER interactions that facilitate mitochondrial calcium overload and result in metabolic dysfunction (39).

Although future investigations will have to clarify the exact localization of TRPV1 in relation to the mitochondria, our analysis of the functional consequences of TRPV1 activation revealed that TRPV1 stimulation by capsaicin induces changes to mitochondrial function identical to those induced by 12(S)-HpETE and high levels of glucose. Our results further show that Trpv1-knockout mice are equally as protected from diabetes-induced endothelial dysfunction and impaired responses to arterial lesions in diabetes as are mice with endothelial 12/15Lof1 knockout. Further analysis showed that 12(S)-HpETE effects were abolished in the presence of BCTC, a well-established TRPV1 antagonist (40), or in endothelial cells isolated from Trpv1-deficient mice, and both BCTC and Trpv1 deletion can preserve mitochondrial function under high-glucose conditions. Under high-glucose conditions, TRPV1 expression in endothelial cells was not affected. Contrary to possible desensitization, high-glucose conditions are reported to rather sensitize TRPV1, resulting in increased agonist-evoked calcium responses in diabetes (41, 42). In dorsal root ganglia, increased TRPV1 sensitivity is suggested to link to early painful diabetic neuropathy (43), further supporting the assumption that TRPV1 signaling is not compromised under diabetic conditions. We thus propose TRPV1 as a central mediator of increased 12(S)-HETE concentrations mediating mitochondrial dysfunction and vascular pathology in diabetes.

In acute scenarios such as ischemia/reperfusion injury, TRPV1 may also confer protection from intracellular localizations and involvement in cellular calcium homeostasis (44). Thus, antagonizing TRPV1 may not be a suitable approach for limiting TRPV1-mediated vascular pathology in diabetes because of possible side effects (45). The interaction site of 12(S)-HpETE with TRPV1 has not been identified so far. Other endogenous agonists sharing lipid structure activate TRPV1 by interacting with a positively charged lysine (K) located at site 710 of the highly conserved C-terminal TRP box of TRPV1 (46). Here, we used a peptide (V1-cal) previously characterized as a potent TRPV1 inhibitor (23) to serve as a peptide decoy for 12(S)-HpETE by mimicking the putative 12(S)-HpETE interaction site–spanning region at the C-terminal end of TRPV1. Notably, in diabetic mice subjected to application of this peptide but not the TAT linker protein, we were unable to detect 12(S)-HETE/ TRPV1 interaction sites for the interruption of 12(S)-HETE/ TRPV1 interaction can represent a pharmacological strategy to preserve vascular integrity under high-glucose conditions.

Taken together, our results characterize increased plasma concentrations of 12(S)-HETE in diabetic patients as a direct mechanistic link to disturbed endothelial calcium homeostasis, mitochondrial pathology, and impaired endothelium-dependent vasodilation. We identify intracellular TRPV1 as the primary mediator of 12(S)-HETE–induced calcium changes and mitochondrial pathology in endothelial cells and suggest that abrogation of 12(S)-HETE/ TRPV1 interaction at the TRPV1 TRP box can preserve endothelial cell function in diabetes. This study may support the use of 12(S)-HETE as a biomarker indicating vascular disease initiation, progression, and severity in diabetic patients and identifies a pharmacological strategy to causally control vascular disease and lower the incidence of comorbidities in patients with diabetes.

**Methods**

*Animals.* C57BL/6J, 12/15Lo/Lo Cdh5Scre/+, 12/15Lo/Lo Cdh5Scre/−, and Trpv1−/− (provided by Jan Siemens, Institute of Pharmacology, Heidelberg, Germany) mice were housed on a 12-hour light/12-hour dark cycle with ad libitum access to food and water in a specified pathogen-free facility. Endothelium-specific knockout was induced in 12/15Lo/Lo Cdh5Scre−/− by injection of 3- to 4-week-old mice with 75 mg/kg tamoxifen daily over 3 consecutive days. Genotypes of 12/15Lo/Lo Cdh5Scre−/−, 12/15Lo/Lo Cdh5Scre/−, and Trpv1−/− were confirmed via PCR and gel electrophoresis using the following primers: 12/15LoLoloxP: up 5′-CATGGGTTCCTGCGTTAGTGG-3′, down 5′-TCACCTCACCAC-TACAGTGAAG-3′; Cre: up 5′-GCGTGCATACCCGGTGTCATG-CAACGA-3′, down 5′-GTTGCGAGATGGCGGCGGCGAACACCATT-3′; Trpv1: up 5′-CTGCTGCTAACATGCTCAATTG-3′, down 5′-TCCCTCACTTGACCATGGA-3′, down 5′-CAGGAGATCTGAGACTCTG-3′.

*Diabetes model.* For the induction of type 1 diabetes mellitus, male and female 6- to 8-week-old C57BL/6J, 12/15Lo/Lo Cdh5Scre−/−, 12/15Lo/Lo Cdh5Scre/−, and Trpv1−/− mice were injected i.p. with a single dose of streptozotocin (180 mg/kg in 0.1 M sodium citrate, pH 4.5). Injection of sodium citrate only served as vehicle control. Induction of diabetes was confirmed by measurement of nonfasted blood glucose levels of at least 200 mg/dL 72 hours after injection using an Accu-Check Performa glucometer (Roche). Blood plasma samples were obtained from the facial vein on the day of sacrifice and stored at −80°C pending analysis. 12(S)-HETE and 15(S)-HETE levels were assessed by ELISA (ADI-900-050 and ADI-900-051, Enzo Life Sciences).

*Pressure myography.* For the assessment of endothelial function, third-order mesenteric resistance arteries were dissected 4 weeks after diabetes induction and mounted on glass cannulas in a vessel chamber (Living Systems Instrumentation) in calcium-free buffer (10 mM HEPES, 140 mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 10 mM glucose, 1 mM EGTA). Experiments were performed in calcium-containing buffer (Ca-free buffer without EGTA including 2 mM MgCl2). After the development of stable myogenic tone at 80 mmHg, vessels were exposed to 10 nM (R)(−)-phenylephrine hydrochloride (Tocris) for maximum constriction. Relaxation response to increasing concentrations of Cch (10−9 to 10−6 M; Tocris) was assessed using digital video edge detection. Dependence of carbamoylcholine effects on intact endothelium and endothelium-dependent nitric oxide release were verified in each vessel by application of 100 μM Nω-nitro-L-arginine.
methyl ester (t-NAME; Tocris) and by analysis of a subset of vessels after endothelial denudation using an air bubble.

**Carotid artery injury.** Two weeks after diabetes induction or vehicle control treatment, mice were anesthetized i.p., and unilateral chemical injury of the common carotid artery was induced by exposure of arteries to 3% ferric chloride for 3 minutes as previously described (49). Mice were sacrificed 3 weeks after surgery, and the left carotid artery was removed and fixed in 4% formaldehyde. Vessels were paraffin-embedded, and cross sections performed every 5 μm were stained with H&E for morphological assessment by a blinded observer using x20 magnification on a Nikon Eclipse Ts2 microscope. The section exhibiting the largest neointimal lesion was selected for quantitative analysis assessing neointimal area and luminal stenosis using ImageJ software (version 1.52a, NIH).

**Peptide application.** The V1-cal peptide and V1-scr, a scrambled version of V1-cal, were synthesized as 1 polypeptide with transactivator of transcription (TAT)47–57 carrier in the following order: N-terminus-TAT47–57-spacer (Gly-Gly)-cargo-C-terminus, as described previously (23) (RATILTEDK, V1-cal; and IDKLRTAEIST, V1-scr). For assessment of endothelial function, mice were injected i.v. with 1 mg/kg/d peptide or equimolar concentrations of TAT 4 weeks after diabetes induction for 4 consecutive days before sacrifice. For neointima assessment, 100 μL of 7.5 mg/mL peptide or equimolar concentrations of TAT protein were loaded into Alzet osmotic minipumps for morphological assessment by a blinded observer using ×20 magnification on a Nikon Eclipse Ts2 microscope. In some experiments, cells were loaded with 1 μM V1-cal or TAT for 5 minutes before exposure to the above mentioned substances.

**Isolation of murine endothelial cells.** Murine pulmonary microvascular endothelial cells (MLMVECs) were isolated from 8- to 15-week-old C57BL/6J or Trpv1−/− mice using magnetic sheep anti-rat IgG-coated Dynabeads (catalog 11035, Invitrogen, Thermo Fisher Scientific) coated with rat anti–mouse CD31 antibody (MEC13.3, BioLegend). In brief, mice were sacrificed by cervical dislocation, and 2–3 lungs were washed in PBS, crushed, and incubated in collagenase solution (20 mg collagenase [C7657, MilliporeSigma], 25 μL 1M CaCl2, 200 μL penicillin-streptomycin, 10 μL DNase, and 20 mL PBS) to obtain a single-cell solution. After filtration through a 70 μm cell strainer, cell solution was centrifuged 10 minutes at 0.4 relative centrifugal force. Pellet was resuspended in 2 mL washing medium (DMEM, 10% FCS, 1% penicillin-streptomycin) and incubated with CD31-coupled anti-rat IgG-coated Dynabeads on a rotator for 45 minutes at 4°C. Tubes were placed in a magnetic separator to separate bead-coupled cells that were then plated on gelatin-coated 60 mm dishes. Upon confluence, sorting was performed twice (passages 2 and 3) with CD31-coupled anti-rat IgG-coated Dynabeads, and obtaining of pure endothelial cells was verified by flow cytometry.

**Endothelial cell calcium dynamics.** For assessment of cytosolic and mitochondrial calcium changes, endothelial cells were loaded with 1 μM Fluor-4 AM or Rhod-2 AM cell-permeant calcium indicators (Thermo Fisher Scientific) for 30 minutes, washed and equilibrated in fresh medium, harvested, and analyzed using a BD Accuri flow cytometer (BD Biosciences). After 10% of cell suspensions were used for recording baseline fluorescence intensity, reagents were applied in 10× concentration and fluorescence intensity monitored continuously for up to 5 minutes. 12(S)-HpETE, 15(S)-HpEET (both Enzo Life Sciences), pertussis toxin (MilliporeSigma), capsaicin, V1-cal, V1-scr, and TAT were used for stimulation. Thapsigargin (Tocris) was used to deplete intracellular ER calcium stores at 1 μM. For calcium-free extracellular conditions, cell suspensions were washed 3 times and medium replaced by calcium-free buffer.

**Mitochondrial membrane potential and mitochondrial function.** Mitochondrial membrane potential was assessed using the JC-10 mitochondrial membrane potential assay kit (ab112134, Abcam) and a BD Accuri flow cytometer or by life cell imaging after loading of cells with 150 nM tetramethylrhodamine methyl ester (Invitrogen, Thermo Fisher Scientific) or following flow cytometry analysis. In
vitro mitochondrial function of HUVECs and isolated MLMVECs was investigated using an XFp Seahorse extracellular flux analyzer (Agilent). Endothelial cells were cultured on miniplates until confluence and exposed to either high d- or l-glucose (MilliporeSigma), capsaicin (Tocris), 12(S)-HpETE (Enzo Life Sciences), phenidone (MilliporeSigma), baicalin (Tocris), 15(S)-HpETE, pertussis toxin, EtOH, or DMSO as vehicle control. In some experiments, cells were loaded with 1 μM of the peptides V1-cal, V1-scr, and TAT. Media were changed to Seahorse XF DMEM (103575-100, Agilent) before analysis. In some experiments, oligomycin, FCCP, and antimycin/rotenone were used as parts of the Mito Stress Test Kit (103010-100, Agilent).

**Western blot.** Cell lysates or isolated mitochondria were resolved by SDS-PAGE and transferred to a PVDF membrane. Proteins were detected by anti-TRPV1 (ACC-030, Alomone Labs), anti-12-lipoxygenase (clone OTI1C3, Novus Biologicals), anti-β-actin (clone BAA3, Thermo Fisher Scientific), anti-vinculin (no. 4650, Cell Signaling Technology), anti-Tom20 (ab56783, Abcam), or anti–GPCR GPR31 antibody (ab75579, Abcam) or membrane fraction cocktail (ab140365, Abcam). For visualization, developing kits for horseradish peroxidase–conjugated secondary antibodies were used.

**Study approval.** All experimental procedures were approved by the Animal Care and Use Committee of North Rhine–Westphalia, Germany (State Agency for Nature, Environment and Consumer Protection [LANUV]; AZ81-02.04.2018.A059).

**Statistics.** Statistical analysis was performed using GraphPad Prism 7 software (GraphPad Software Inc.). For comparison of treatment versus control group, Student’s 2-tailed t test or, for the comparison of 3 or more groups, 1-way ANOVA followed by Bonferroni’s correction for multiple comparisons was used. For repeated comparisons of multiple groups over time, 2-way ANOVA followed by Bonferroni’s correction was used. A P value of less than 0.05 was considered statistically significant. Data are presented as mean ± SEM.

**Author contributions**

MO designed research studies, conducted experiments, and acquired and analyzed the data. CB, WL, MM, TS, MK, MND, and JR conducted experiments and acquired and analyzed the data. ERG designed research studies, provided reagents, and revised the manuscript. NMW designed research studies, conducted experiments, acquired and analyzed the data, and wrote the manuscript.

**Acknowledgments**

The authors thank Peter Reeh, Institute of Physiology and Pathophysiology, University of Erlangen-Nürnberg, Erlangen, Germany, for providing isolated murine dorsal root ganglia; Jan Siemens for providing Trpv1-knockout mice; and Cornelia Richter-Elsenheimer, Christa Post, Veronica Haase, and Elke Nass for providing excellent technical assistance. This work was funded by grants from the Deutsche Forschungsgemeinschaft (German Research Foundation) to NW (WA3786/2-1 and WA3786/3-1) and from the NIH to ERG (National Institute of General Medical Sciences GM119522).

**Address correspondence to:** Nana-Maria Wagner, Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany. Phone: 0049.251.82.46837; Email: nmwagner@uni-muenster.de.

WL’s present address is: Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Heart Assoc. 2016;5(9):e003774.